DOI QR코드

DOI QR Code

Validation of Customized Cancer Panel for Detecting Somatic Mutations and Copy Number Alterations

  • Choi, Su-Hye (Department of Microbiology, College of Medicine, The Catholic University of Korea) ;
  • Jung, Seung-Hyun (Integrated Research Center for Genome Polymorphism, College of Medicine, The Catholic University of Korea) ;
  • Chung, Yeun-Jun (Department of Microbiology, College of Medicine, The Catholic University of Korea)
  • Received : 2017.11.23
  • Accepted : 2017.11.28
  • Published : 2017.12.31

Abstract

Accurate detection of genomic alterations, especially druggable hotspot mutations in tumors, has become an essential part of precision medicine. With targeted sequencing, we can obtain deeper coverage of reads and handle data more easily with a relatively lower cost and less time than whole-exome or whole-genome sequencing. Recently, we designed a customized gene panel for targeted sequencing of major solid cancers. In this study, we aimed to validate its performance. The cancer panel targets 95 cancer-related genes. In terms of the limit of detection, more than 86% of target mutations with a mutant allele frequency (MAF) <1% can be identified, and any mutation with >3% MAF can be detected. When we applied this system for the analysis of Acrometrix Oncology Hotspot Control DNA, which contains more than 500 COSMIC mutations across 53 genes, 99% of the expected mutations were robustly detected. We also confirmed the high reproducibility of the detection of mutations in multiple independent analyses. When we explored copy number alterations (CNAs), the expected CNAs were successfully detected, and this result was confirmed by target-specific genomic quantitative polymerase chain reaction. Taken together, these results support the reliability and accuracy of our cancer panel in detecting mutations. This panel could be useful for key mutation profiling research in solid tumors and clinical translation.

Keywords

References

  1. Davey JW, Hohenlohe PA, Etter PD, Boone JQ, Catchen JM, Blaxter ML. Genome-wide genetic marker discovery and genotyping using next-generation sequencing. Nat Rev Genet 2011;12:499-510. https://doi.org/10.1038/nrg3012
  2. Fontanges Q, De Mendonca R, Salmon I, Le Mercier M, D'Haene N. Clinical application of targeted next generation sequencing for colorectal cancers. Int J Mol Sci 2016;17:E2117. https://doi.org/10.3390/ijms17122117
  3. Chen A, Conley B, Hamilton S, Williams M, O'Dwyer P, Arteaga C, et al. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: a novel public-private partnership. Eur J Cancer 2016;69(Suppl 1):S137.
  4. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 2011;32:177-195.
  5. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res 2015;4:256-269.
  6. Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today 2015;20:1422-1428. https://doi.org/10.1016/j.drudis.2015.08.005
  7. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015;7:302ra133. https://doi.org/10.1126/scitranslmed.aab0021
  8. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 2015;33:2753-2762. https://doi.org/10.1200/JCO.2014.60.4165
  9. Shah PD, Nathanson KL. Application of panel-based tests for inherited risk of cancer. Annu Rev Genomics Hum Genet 2017;18:201-227. https://doi.org/10.1146/annurev-genom-091416-035305
  10. Goodwin S, McPherson JD, McCombie WR. Coming of age:ten years of next-generation sequencing technologies. Nat Rev Genet 2016;17:333-351.
  11. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164. https://doi.org/10.1093/nar/gkq603
  12. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol 2011;29:24-26. https://doi.org/10.1038/nbt.1754
  13. Rathi V, Wright G, Constantin D, Chang S, Pham H, Jones K, et al. Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens. Pathology 2017;49:75-82. https://doi.org/10.1016/j.pathol.2016.08.016
  14. Vendrell JA, Grand D, Rouquette I, Costes V, Icher S, Selves J, et al. High-throughput detection of clinically targetable alterations using next-generation sequencing. Oncotarget 2017;8:40345-40358.
  15. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56-65. https://doi.org/10.1038/nature11632
  16. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016;536:285-291. https://doi.org/10.1038/nature19057
  17. Forbes SA, Beare D, Bindal N, Bamford S, Ward S, Cole CG, et al. COSMIC: high-resolution cancer genetics using the catalogue of somatic mutations in cancer. Curr Protoc Hum Genet 2016;91:10.11.1-10.11.37.
  18. AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov 2017;7:818-831. https://doi.org/10.1158/2159-8290.CD-17-0151

Cited by

  1. Comparison of the Genetic Alterations between Primary Colorectal Cancers and Their Corresponding Patient-Derived Xenograft Tissues vol.16, pp.2, 2018, https://doi.org/10.5808/GI.2018.16.2.30